Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00321152 · ClinicalTrials.gov registry record · Phase 4
A Study of 6(S)-5-MTHF Among Serotonin Reuptake Inhibitor(SSRI)-Resistant Outpatients With Major Depressive Disorder (MDD)
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 150
- Enrollment target
NCT00321152: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT00321152 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 150 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00321152, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 150 participants
- Enrollment target
Study Summary
The purpose of the study is to test whether oral 6(S)-5-MTHF (Deplin®) is safe and effective in relieving depression when it is added to standard kinds of antidepressants called serotonin reuptake inhibitors (SSRIs).
Interventions
- OTHER 6(S)-5-MTHF (a Medical Food)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2006-11 |
| Est. Completion | 2010-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00321152
The ClinicalTrials.gov registry entry for NCT00321152 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 6(S)-5-MTHF (a Medical Food) is the first listed.
NCT00321152 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00321152 about?
NCT00321152 is a clinical study titled "A Study of 6(S)-5-MTHF Among Serotonin Reuptake Inhibitor(SSRI)-Resistant Outpatients With Major Depressive Disorder (MDD)". The purpose of the study is to test whether oral 6(S)-5-MTHF (Deplin®) is safe and effective in relieving depression when it is added to standard kinds of antidepressants called serotonin reuptake inhibitors (SSRIs).
What is the current status of trial NCT00321152?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 150 participants. The study started on 2006-11. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00321152?
The interventions under investigation include: 6(S)-5-MTHF (a Medical Food) (OTHER).
Who is sponsoring clinical trial NCT00321152?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.